financetom
Business
financetom
/
Business
/
Intra-Cellular Therapies Posts Unchanged Q3 Net Loss, Revenue Rises
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Intra-Cellular Therapies Posts Unchanged Q3 Net Loss, Revenue Rises
Oct 30, 2024 9:59 PM

08:07 AM EDT, 10/30/2024 (MT Newswires) -- Intra-Cellular Therapies ( ITCI ) reported a Q3 net loss Wednesday of $0.25 per diluted share, unchanged from a year earlier.

Analysts polled by Capital IQ expected a loss of $0.21.

Total revenue for the quarter ended Sept. 30 was $175.4 million, compared with $126.2 million a year earlier.

Analysts surveyed by Capital IQ expected $172.4 million.

Intra-Cellular shares were nearly 3% higher in premarket trading.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Copyright 2023-2026 - www.financetom.com All Rights Reserved